9,141 Hits in 3.6 sec

Computational modelling of atherosclerosis: developing a community resource [article]

Andrew Parton, Victoria McGilligan, Maurice O'Kane, Steven Watterson
2018 bioRxiv   pre-print
We used this model to investigate whether multi-drug therapeutic interventions could be identified that stimulate plaque regression.  ...  We used a genetic algorithm to identify a multi-drug intervention hypothesis comprising five drugs that comprehensively reverse plaque growth within the model.  ...  Here, we employ the model to develop 21 effective therapeutic hypotheses comprising multi-drug combinations.  ... 
doi:10.1101/256750 fatcat:5kjoqwftinhxheufe3jp7zhlgu

Imaging and Nanomedicine in Inflammatory Atherosclerosis

W. J. M. Mulder, F. A. Jaffer, Z. A. Fayad, M. Nahrendorf
2014 Science Translational Medicine  
This review describes how the integration of engineering, nanotechnology, and cardiovascular immunology may yield precision diagnostics and efficient therapeutics for atherosclerosis and its ischemic complications  ...  The first multicenter trials highlight the potential contribution of multimodality imaging to more efficient drug development.  ...  A second emerging field within biomedical engineering is intelligent drug delivery. Recent insights into the immunology of atherosclerosis offer new therapeutic points of attack ( Figs. 1 and 3 ).  ... 
doi:10.1126/scitranslmed.3005101 pmid:24898749 pmcid:PMC4110972 fatcat:uleyc4xi7zhwhlkiswsrj7fvoa

Break the Cycle: The Role of Cell-Cycle Modulation in the Prevention of Vasculoproliferative Diseases

J.E. Ferguson, Cam Patterson
2003 Cell Cycle  
Atherosclerosis is a major health problem in the western world, and the effectiveness of interventional therapeutic modalities for symptomatic atherosclerotic lesions is limited by vessel restenosis.  ...  Proliferation and migration of smooth muscle cells (SMCs) play a central role in post-interventional restenosis. Accordingly, many therapeutic approaches attempt to inhibit SMC proliferation.  ...  This animal model has proven quite useful in evaluating the therapeutic efficacy of drug-eluting stent technologies for in-stent restenosis (described below).  ... 
doi:10.4161/cc.2.3.366 fatcat:ihowuavsefcqpdcxawgmrnywaq

Bioengineering of the heart

Alberto Redaelli, Justin Cooper-White
2020 APL Bioengineering  
on the function of this complex system, how we may mimic aspects of human biology and pathology with in vitro cardiac tissue models, and how drug and therapeutic discovery with new human cell-based drug  ...  two papers describing state-of-the art animal models that provide new insights into early pathology of dissecting abdominal aortic aneurysm formation in apolipoprotein E-deficient mice 4 and into cardiomyocyte  ...  on the function of this complex system, how we may mimic aspects of human biology and pathology with in vitro cardiac tissue models, and how drug and therapeutic discovery with new human cell-based drug  ... 
doi:10.1063/1.5144525 pmid:32161832 pmcid:PMC7056452 fatcat:cj23ripavbce7o2t6ki7gzfgj4

Targeting innate immunity for CV benefit

Kathryn J. Moore, Mason W. Freeman
2008 Drug Discovery Today : Therapeutic Strategies  
Specific emphasis will be placed on the potential of these innate immune targets for therapeutic interventions to retard the progression of atherosclerosis or to induce its regression.  ...  The initiation and progression of vascular inflammation are driven by the retention of cholesterol in the artery wall, where its modification by oxidation and/or enzymes triggers the innate immune host  ...  models of atherosclerosis.  ... 
doi:10.1016/j.ddstr.2008.05.007 pmid:19430537 pmcid:PMC2678718 fatcat:2425wu373fejhnkjgoaliocjyu

Editorial: Lipids and Inflammation in Health and Disease

Evgeny Bezsonov, Vasily Sukhorukov, Michael Bukrinsky, Alexander Orekhov
2022 Frontiers in Cardiovascular Medicine  
a new drug target for therapy of atherosclerosis.  ...  A better understanding of the nature and mechanisms of chemical modifications of LDL particles leading to their atherogenicity can help to find new therapeutic options to treat atherosclerosis.  ...  We hope that the next SI will continue traditions of highquality research and reviews established by the current one.  ... 
doi:10.3389/fcvm.2022.864429 pmid:35369350 pmcid:PMC8964976 fatcat:2ojjcxlkrjdkdevfprdskaxvc4

Advances in nanotechnology for the management of coronary artery disease

June-Wha Rhee, Joseph C. Wu
2013 Trends in cardiovascular medicine  
Keywords Nanotechnology; coronary artery disease; atherosclerosis; percutaneous coronary intervention; coronary artery bypass graft Nanotechnology and Medicine Nanotechnology enables the engineering of  ...  nanoparticle-based delivery of drugs that are decoupled from stents.  ...  Acknowledgments This work was supported in part by Burroughs Wellcome Foundation, NIH R01HL093172, NIH R01HL095571, NIH R33 HL089027, and NIH R01EB009689 (JCW).  ... 
doi:10.1016/j.tcm.2012.08.009 pmid:23245913 pmcid:PMC3566293 fatcat:n6mdetswrng75hkjvzethl63xi

Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis

Bin Li, Weihong Li, Xiaoli Li, Hong Zhou
2017 Current pharmaceutical design  
Here, we review the current development of inflammation and atherosclerosis to discuss novel insights and potential targets in atherosclerosis, and to address drug discovery based on anti-inflammatory  ...  However, treatment targeting the inflammatory nature of atherosclerosis is still very limited and deserves further attention to fight atherosclerosis successfully.  ...  Drug Discovery and Targets Based on the Role of TLRs in Atherosclerosis Given the role of TLRs pathway in the pathogenesis of atherosclerosis, therapeutic targeting of TLRs by drugs could have tremendous  ... 
doi:10.2174/1381612822666161230142931 pmid:28034355 fatcat:4ybiv2xfr5arrhdx4idfk7vlii

Prevalence of Traditional Modifiable Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis: Comparison with Control Subjects from the Multi-Ethnic Study of Atherosclerosis

Cecilia P. Chung, Jon T. Giles, Michelle Petri, Moyses Szklo, Wendy Post, Roger S. Blumenthal, Allan C. Gelber, Pamela Ouyang, Nancy S. Jenny, Joan M. Bathon
2012 Seminars in Arthritis & Rheumatism  
Rates of therapeutic interventions were low in both groups but their use was associated with well-controlled blood pressure (OR = 4.55, 95% CI: 1.70, 12.19) and lipid levels (OR = 9.90, 95% CI: 3.30, 29.67  ...  Despite the recognized risk of accelerated atherosclerosis in patients with rheumatoid arthritis (RA), little is known about cardiovascular risk management in contemporary cohorts of these patients.  ...  The risk of drug-to-drug interactions, side effects, and poor compliance are other potential barriers to therapeutic interventions in patients with multiple chronic conditions (39) .  ... 
doi:10.1016/j.semarthrit.2011.07.004 pmid:22340996 pmcid:PMC3538033 fatcat:ckaiefyvcffs7arced4criqbie

Systems biology in drug discovery and development

Ellen L. Berg
2014 Drug Discovery Today  
Such concepts include proteomics, cell behavior, interactomes, and multi-drug targets.  ...  In the mean time, although the industry is spending a tremendous amount of money and time, high-profile drug withdrawals are increasing, with fewer FDA approvals of new drugs.  ...  Such concepts include proteomics, cell behavior, interactomes, and multi-drug targets.  ... 
doi:10.1016/j.drudis.2013.10.003 pmid:24120892 fatcat:jynrkxunqzh2tkm32rlv6jj3ri

Nanomaterial-Mediated Theranostics for Vascular Diseases

Swati Agrawal, Sunil K. Nooti, Harbinder Singh, Vikrant Rai
2020 Journal of Nanotheranostics  
Nanotechnology can mitigate the pathological events by enhancing the therapeutic efficacy of the therapeutic agent by delivering it at the point of a lesion in a controlled and efficacious manner.  ...  Further, combining therapeutics with imaging will enhance the theranostic ability in atherosclerosis.  ...  Conflicts of Interest: The authors declare no conflict of interest.  ... 
doi:10.3390/jnt2010001 fatcat:fk5krd4havbjjjiv3ubo6x4qoy

Nanomaterials as Novel Cardiovascular Theranostics

Rajasekharreddy Pala, Subhaswaraj Pattnaik, Siddhardha Busi, Surya M. Nauli
2021 Pharmaceutics  
The differential physicochemical properties of engineered nanoparticles have been exploited for early diagnosis and therapy of atherosclerosis, myocardial infarction and aneurysms.  ...  Conventionally, diagnostic tools are employed to detect disease conditions, whereas therapeutic drug candidates are administered to mitigate diseases.  ...  Thus, hybrid nanomaterials could provide a new basis for atherosclerosis prognosis and therapeutic management [66] .  ... 
doi:10.3390/pharmaceutics13030348 pmid:33799932 pmcid:PMC7998597 fatcat:m6amksbsk5f77mxzkxsnyobnmq

GW26-e1387 The Expression of HSP22 in Atherosclerotic apoE-Deficient (ApoE-/-) Mice and Therapeutic Impact by Atorvastatin

Xiaoli Tu, Qi Chen, Hongzhou Zhang, Ruijuan Yan, Yanqing Wu
2015 Journal of the American College of Cardiology  
The expression of eNOS in HFD model group and statins intervention group were decreased compared with the ND control group (P<0.01), however statins intervention group expressed more eNOS than HFD model  ...  The expression of HSP22 protein in serum and aorta in HFD model group and statins intervention group were significantly increased compared with ND control group (P<0.01) and statins intervention group  ... 
doi:10.1016/j.jacc.2015.06.1114 fatcat:27r26a2hq5f5heidgcjsa6kreu

Atherosclerosis and Nanotechnology: Diagnostic and Therapeutic Applications

Jeremy D. Kratz, Ashish Chaddha, Somnath Bhattacharjee, Sascha N. Goonewardena
2016 Cardiovascular Drugs and Therapy  
and therapeutic management of CAD.  ...  To realize this potential we must go beyond to recognize new frontiers including knowledge gaps between understanding atherosclerosis to the translation of targeted molecular tools.  ...  G. was supported by a Samuel and Jean Frankel Cardiovascular Center Inaugural Grant and by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K08HL123621  ... 
doi:10.1007/s10557-016-6649-2 pmid:26809711 pmcid:PMC4791194 fatcat:vbxjz3uhybhavmqybsft6svrvq

The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy

Francesco Nappi, Antonio Nenna, Domenico Larobina, Giorgia Martuscelli, Sanjeet Singh Avtaar Singh, Massimo Chello, Luigi Ambrosio
2021 Polymers  
The conceptual and technologic evolution of these devices from bare-metal stents led to the creation and wide application of drug-eluting stents; further research introduced the idea of polymer-based resorbable  ...  as percutaneous coronary intervention (PCI).  ...  Conflicts of Interest: The authors declare no conflict of interest.  ... 
doi:10.3390/polym13030446 pmid:33573282 pmcid:PMC7866823 fatcat:q54jgagnlvghfeziz6xlgb6lna
« Previous Showing results 1 — 15 out of 9,141 results